Acute bacterial meningitis in adults
Over the past several decades, the incidence of bacterial meningitis in children has
decreased but there remains a significant burden of disease in adults, with a mortality of up …
decreased but there remains a significant burden of disease in adults, with a mortality of up …
Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)
Abstract Background Individual-based models (IBMs) are useful to simulate events subject
to stochasticity and/or heterogeneity, and have become well established to model the …
to stochasticity and/or heterogeneity, and have become well established to model the …
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1+ 1) compared with two primary doses and a booster (2+ 1) in UK infants: a …
D Goldblatt, J Southern, NJ Andrews… - The Lancet Infectious …, 2018 - thelancet.com
Background Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7)
in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2+ 1 schedule). A …
in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2+ 1 schedule). A …
Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England
J Southern, N Andrews, P Sandu, CL Sheppard… - PLoS …, 2018 - journals.plos.org
Background In April 2010, 13-valent pneumococcal conjugate vaccine (PCV13) replaced
PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype …
PCV7 in the infant immunisation schedule in England and Wales. Despite limited serotype …
Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children< 5 years: an active prospective nationwide …
S Ben-Shimol, D Greenberg, N Givon-Lavi… - Vaccine, 2014 - Elsevier
Background The 7-valent pneumococcal conjugated vaccine (PCV7) was introduced to the
Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 …
Israeli national immunization plan (NIP) in July 2009 (administered at age 2, 4 and 12 …
Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom
M Wilson, A Lucas, D Mendes, A Vyse, B Mikudina… - Vaccines, 2023 - mdpi.com
Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a
1+ 1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs …
1+ 1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs …
Estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+ 1 to 1+ 1 in England and Wales: A modelling study
Background In October 2017, the United Kingdom Joint Committee on Vaccination and
Immunisation (JCVI) recommended removal of one primary dose of the 13-valent …
Immunisation (JCVI) recommended removal of one primary dose of the 13-valent …
[HTML][HTML] Community and campus COVID-19 risk uncertainty under university reopening scenarios: Model-based analysis
J Benneyan, C Gehrke, I Ilies… - JMIR public health and …, 2021 - publichealth.jmir.org
Background: Significant uncertainty has existed about the safety of reopening college and
university campuses before the COVID-19 pandemic is better controlled. Moreover, little is …
university campuses before the COVID-19 pandemic is better controlled. Moreover, little is …
Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1+ 1 infant schedule …
YH Choi, M Bertran, DJ Litt, SN Ladhani… - The Lancet Public …, 2024 - thelancet.com
Background Paediatric pneumococcal conjugate vaccine (PCV) programmes in England
using seven-valent PCV (PCV7) in 2006 and 13-valent PCV (PCV13) in 2010 have reduced …
using seven-valent PCV (PCV7) in 2006 and 13-valent PCV (PCV13) in 2010 have reduced …
Immunization, antibiotic use, and pneumococcal colonization over a 15-year period
BACKGROUND: Rates of invasive pneumococcal disease have declined since widespread
introduction of pneumococcal conjugate vaccines (PCVs) in the United States. We evaluated …
introduction of pneumococcal conjugate vaccines (PCVs) in the United States. We evaluated …